Reports
As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
Global Anticoagulants Market: By Drug Class: Novel Oral Anticoagulants (NOACs), Heparin and Low Molecular Weight Heparin (LMWH), Vitamin K Antagonist; By Application; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics: SWOT Analysis; Competitive Landscape; Industry Events and Developments
Global Anticoagulants Market Outlook
The global anticoagulants market is expected to grow in the forecast period of 2022-2027 at a CAGR of about 9.35%.
North America has a Significant Market Share in the Anticoagulants Industry
North America is one of the major markets in the anticoagulants industry. This can be attributed to the increase in the incidence rate of cardiovascular diseases in North America. According to Centres for Disease Control and Prevention, one in every 4 deaths is caused by heart disease, i.e., about 655,000 Americans die from heart disease each year. Further, a well-established healthcare infrastructure, along with the presence of key pharma and biotech companies, is supporting the entire regional market's expansion to a great extent.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Cases of Cardiovascular Diseases in Europe and the Asia Pacific to Augment the Market Growth
Europe is also a significant contributor to the anticoagulants industry. According to the European Society of Cardiology (ESC), the region witnesses more than 11 million new cases of cardiovascular diseases (CVD) on the whole every year, as per 2019 statistics. In the EU, about 49 million people are currently living with this condition. Further, as per ESC, CVD is the leading cause of death in Europe, accounting for about 45% of all deaths and 37% in the EU. Meanwhile, major countries in the Asia Pacific, such as China, are also rising cases of CVD. China is witnessing an increasing mortality rate attributed to CVD. In 2016, as reported by the Journal of Geriatric Cardiology, cardiovascular disease (CVD) was the top cause of mortality in both rural and urban areas, accounting for 45.50% and 43.16% of all deaths, respectively. This is likely to make China an emerging market for anticoagulants in the forecast period.
Anticoagulants: Industry Definition and Segmentation
Anticoagulants are referred to as those drugs that prevent the formation of blood clots. They're given to those who have a high risk of blood clots to help them avoid catastrophic diseases, including strokes and heart attacks. Anticoagulants act by inhibiting the process that causes the formation of blood clots. They are also known as "blood thinners".
On the basis of drug class, the market can be classified into:
- Novel Oral Anticoagulants (NOACs)
- Heparin and Low Molecular Weight Heparin (LMWH)
- Vitamin K Antagonist
The market can be broadly categorised on the basis of its applications into:
- Atrial Fibrillation/Myocardial Infarction (Heart Attack)
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism
- Others
The EMR report looks into the regional markets of anticoagulants like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Rising Lifestyle Risks Like Obesity and Diabetes to Boost the Anticoagulants Industry
The growing lifestyle risks like diabetes and obesity, along with the growing health awareness among the public, currently require better and efficient treatments. The introduction of NOACs has resulted in a significant increase in anticoagulant use and expenditure. The development of pharmaceuticals and therapeutic companies is boosting the production and efficiency of anticoagulants. This is augmenting the market growth of anticoagulants. The risks and threats for health posed by COVID-19 have boosted investments in the anticoagulant industry. The growing healthcare expenditure by the government, along with key market players, is a huge driving force for the market. There are strict government regulations attributed to the safety and dosage of anticoagulants. The FDA approval of anticoagulants usage for paediatric heart patients in 2019 is also a huge boost to the industry.
Key Industry Players in the Global Anticoagulants Market
The report presents a detailed analysis of the following key players in the global anticoagulants market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Johnson & Johnson Services, Inc.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company, Limited
- GlaxoSmithKline plc
- Aspen Pharmacare Holdings Limited
- Pfizer Inc.
- Portola Pharmaceuticals, Inc.
- Others
The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2020 |
| Historical Period | 2017-2021 |
| Forecast Period | 2022-2027 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Drug Class, Application, Region |
| Breakup by Drug Class | Novel Oral Anticoagulants (NOACs), Heparin and Low Molecular Weight Heparin (LMWH), Vitamin K Antagonist |
| Breakup by Application | Atrial Fibrillation/Myocardial Infarction (Heart Attack), Deep Vein Thrombosis (DVT), Pulmonary Embolism, Others |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Johnson & Johnson Services, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc, Aspen Pharmacare Holdings Limited, Pfizer Inc., Portola Pharmaceuticals, Inc., Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Anticoagulants Market Analysis
8.1 Key Industry Highlights
8.2 Global Anticoagulants Historical Market (2017-2021)
8.3 Global Anticoagulants Market Forecast (2022-2027)
8.4 Global Anticoagulants Market by Drug Class
8.4.1 Novel Oral Anticoagulants (NOACs)
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.2 Heparin and Low Molecular Weight Heparin (LMWH)
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.4.3 Vitamin K Antagonist
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2017-2021)
8.4.3.3 Forecast Trend (2022-2027)
8.5 Global Anticoagulants Market by Application
8.5.1 Atrial Fibrillation/Myocardial Infarction (Heart Attack)
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2017-2021)
8.5.1.3 Forecast Trend (2022-2027)
8.5.2 Deep Vein Thrombosis (DVT)
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2017-2021)
8.5.2.3 Forecast Trend (2022-2027)
8.5.3 Pulmonary Embolism
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2017-2021)
8.5.3.3 Forecast Trend (2022-2027)
8.5.4 Others
8.6 Global Anticoagulants Market by Region
8.6.1 Market Share
8.6.1.1 North America
8.6.1.2 Europe
8.6.1.3 Asia Pacific
8.6.1.4 Latin America
8.6.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 EMR’s Key Indicators for Demand
10.4 EMR’s Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 Johnson & Johnson Services, Inc.
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 Bayer AG
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 Boehringer Ingelheim International GmbH
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Bristol-Myers Squibb Company
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 Daiichi Sankyo Company, Limited
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 GlaxoSmithKline plc
12.2.6.1 Company Overview
12.2.6.2 Product Portfolio
12.2.6.3 Demographic Reach and Achievements
12.2.6.4 Certifications
12.2.7 Aspen Pharmacare Holdings Limited
12.2.7.1 Company Overview
12.2.7.2 Product Portfolio
12.2.7.3 Demographic Reach and Achievements
12.2.7.4 Certifications
12.2.8 Pfizer Inc.
12.2.8.1 Company Overview
12.2.8.2 Product Portfolio
12.2.8.3 Demographic Reach and Achievements
12.2.8.4 Certifications
12.2.9 Portola Pharmaceuticals, Inc.
12.2.9.1 Company Overview
12.2.9.2 Product Portfolio
12.2.9.3 Demographic Reach and Achievements
12.2.9.4 Certifications
12.2.10 Others
13 Industry Events and Developments
List of Figures and Tables
1. Global Anticoagulants Market: Key Industry Highlights, 2016 and 2026
2. Global Anticoagulants Historical Market: Breakup by Drug Class (USD Million), 2017-2021
3. Global Anticoagulants Market Forecast: Breakup by Drug Class (USD Million), 2022-2027
4. Global Anticoagulants Historical Market: Breakup by Application (USD Million), 2017-2021
5. Global Anticoagulants Market Forecast: Breakup by Application (USD Million), 2022-2027
6. Global Anticoagulants Historical Market: Breakup by Region (USD Million), 2017-2021
7. Global Anticoagulants Market Forecast: Breakup by Region (USD Million), 2022-2027
8. North America Anticoagulants Historical Market: Breakup by Country (USD Million), 2017-2021
9. North America Anticoagulants Market Forecast: Breakup by Country (USD Million), 2022-2027
10. Europe Anticoagulants Historical Market: Breakup by Country (USD Million), 2017-2021
11. Europe Anticoagulants Market Forecast: Breakup by Country (USD Million), 2022-2027
12. Asia Pacific Anticoagulants Historical Market: Breakup by Country (USD Million), 2017-2021
13. Asia Pacific Anticoagulants Market Forecast: Breakup by Country (USD Million), 2022-2027
14. Latin America Anticoagulants Historical Market: Breakup by Country (USD Million), 2017-2021
15. Latin America Anticoagulants Market Forecast: Breakup by Country (USD Million), 2022-2027
16. Middle East and Africa Anticoagulants Historical Market: Breakup by Country (USD Million), 2017-2021
17. Middle East and Africa Anticoagulants Market Forecast: Breakup by Country (USD Million), 2022-2027
18. Global Anticoagulants Market Structure
Key Questions Answered in the Report
The global anticoagulants market is projected to grow at a CAGR of 9.35% between 2021 and 2026.
The growing incidence of cardiovascular diseases, growing lifestyle risks, and growing health awareness are leading the market growth.
The adoption of more efficient and safer anticoagulants like NOACs is expected to influence the market over the forecast period.
The major regions in the market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
The different drug classes of anticoagulants are novel oral anticoagulants (NOACs), heparin and low molecular weight heparin (LMWH), vitamin K antagonist.
The anticoagulants find its applications in the treatment of atrial fibrillation/myocardial infarction (heart attack), and deep vein thrombosis (DVT), and pulmonary embolism, among others.
The major players in the industry are Johnson & Johnson Services, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc, Aspen Pharmacare Holdings Limited, Pfizer Inc., and Portola Pharmaceuticals, Inc., among others.
Analyst Review
The global anticoagulants market is driven by the rising prevalence of various cardiovascular diseases. Aided by the growing adoption of safer and more efficient anticoagulants, the market is expected to witness a further growth in the forecast period of 2022-2027, growing at a CAGR of 9.35%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its drug class, the anticoagulants industry can be segmented into novel oral anticoagulants (NOACs), heparin and low molecular weight heparin (LMWH), and vitamin K antagonist. On the basis of application, the industry is divided into atrial fibrillation/myocardial infarction (heart attack), deep vein thrombosis (DVT), and pulmonary embolism, among others. The major regional markets for anticoagulants are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Johnson & Johnson Services, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc, Aspen Pharmacare Holdings Limited, Pfizer Inc., and Portola Pharmaceuticals, Inc., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateFive User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?RIGHT PEOPLE
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
RIGHT METHODOLOGY
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
RIGHT PRICE
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
RIGHT SUPPORT
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
The global oral antibiotics market attained a value of over USD 18,365.8 million in 2021, driven by the extensive use of oral antibiotics for the treatment of infectious diseases. Aided by the growing...
The Asia Pacific vaccine market attained a value of nearly USD 3.92 billion in 2021, driven by the robust growth of the healthcare sector. Aided by the increasing research and development (R&D) activi...
The global microencapsulation market attained a value of about USD 9.52 billion in 2021, driven by the advancements in the pharmaceutical and nutraceutical industries. Aided by growing inclination tow...
The global anti-infectives market attained a value of about USD 118.36 billion in 2021, driven by the rising prevalence of infectious diseases. Aided by large scale investments into the pharmaceutical...
The global liposomal doxorubicin market attained a value of more than USD 1,100 million in 2021, driven by the increase in breast and ovarian cancer cases, as well as increased awareness of the advant...
NEWSLETTER